About Prothena
Prothena is a company based in Dublin (Ireland) founded in 2012. The company has 163 employees. Prothena offers products and services including Birtamimab, Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), and PRX012. Prothena operates in a competitive market with competitors including Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
- Headquarter Dublin, Ireland
- Employees 163
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website prothena.com
- Social LinkedIn X
- Legal Name Prothena Corporation Plc
- Annual Revenue$9.68 M (USD)-92.83as on Dec 31, 2025
- Net Profit-$244.09 M (USD)-99.57as on Dec 31, 2025
- EBITDA-$180.86 M (USD)-19.79as on Dec 31, 2025
- Latest Funding Round$50M (USD), Post-IPO
Mar 2018
- Employee Count163
Products & Services of Prothena
Prothena offers a comprehensive portfolio of products and services, including Birtamimab, Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), and PRX012.
Investigational drug for AL Amyloidosis treatment in trials.
Drug candidate for Parkinson’s Disease management.
Targets ATTR Amyloidosis in clinical development.
Investigational option for specific amyloid-related conditions.
Candidate for Alzheimer’s Disease therapeutic applications.
Funding Insights of Prothena
- Total Rounds 1
- Last Round Post-IPO — $50M
- First Round $50M
(Mar 2018)
All 1 funding rounds of Prothena with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $50M | Post-IPO | – | – | – |
People of Prothena
60 people are tracked at Prothena (41 in leadership, 8 in board & advisors, 11 in team); the tracked headcount is 163.
| Name | Role | Group |
|---|---|---|
Gene G. Kinney | President & CEO | Leadership |
Karin L. Walker | Chief Accounting Officer & Controller | Leadership |
Karen Quadrini | Director, Clinical Biomarkers | Leadership |
Connie Cyras | Senior Director Portfolio And Alliance Management | Leadership |
Annie Kingston | Vp, Corporate Strategy And Chief Of Staff, Office Of The CEO | Leadership |
Donna Lepera | Vice President, Global Safety And Pharmacovigilance Operations | Leadership |
Brandon Smith | Chief Business Officer | Leadership |
Tran B. Nguyen | COO & CFO | Leadership |
Karisa Jaramillo | Senior Director, Us/global Brand Lead (rare Disease) | Leadership |
Michael J. Malecek | Chief Legal Officer and Company Secretary | Leadership |
Mike Malecek | Chief Legal Officer | Leadership |
Wagner M. Zago | Chief Scientific Officer | Leadership |
Chi J. | Associate Director, Facilities And Eh&s | Leadership |
Lisa Tucker | Associate Director- Global Monitoring Operations | Leadership |
Dave Ford | Chief People Officer | Leadership |
Dan Zweifel | Director Of Clinical Pharmacology And Translational Medicine | Leadership |
Ansgar Conrad | Vice President, Medical Affairs & Patient Advocacy | Leadership |
Neha V. | VP Finance, Controller | Leadership |
Karen L. | Director, Clinical Science (rare Disease) | Leadership |
Mary Desouza (Mimi) | Vice President, Product Team Lead | Leadership |
40 more people are available in the full profile.
Complete people profiles for Prothena
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Prothena
Prothena is a publicly listed company on the NASDAQ with ticker symbol PRTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2013
- Listed onNASDAQ: PRTA
- Listed entityProthena Corporation plc
- Exchange sectorHealth technology
- ISINIE00B91XRN20
- Share price$8.84 (+2.67% on the day) · 2026-10-09
- Market capitalisation$453.8M
- EPS (diluted, trailing year)$-0.83
- Volume (last session)931,625
Financials of Prothena
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $9.7M | -$244.1M | -$180.9M |
| 2024 | $135.2M | -$122.3M | -$151.0M |
| 2023 | $91.4M | -$147.0M | -$182.6M |
| 2022 | $53.9M | -$117.0M | -$124.8M |
| 2021 | $200.6M | $67.0M | $78.8M |
Detailed financial statements for Prothena
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Prothena
3 dated milestones of Prothena across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Prothena is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $50.0M.
Competitors of Prothena
Prothena operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| pacira.com | 2006 | Parsippany Troy Hills, United States | $85M | 712 | Injectable non-opioid products for post-surgical pain control are developed. | |
| neumoratx.com | 2020 | Watertown, United States | $612M | 125 | Precision medicines for neuropsychiatric and neurodegenerative disorders are developed. |
Detailed competitors of Prothena
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Prothena
The website of Prothena (prothena.com) receives about 5.6K visits a month and ranks #3,145,374 among all websites worldwide, #4,142 in Biotechnology and Pharmaceuticals.
- Monthly visits5.6K
▼ 15.7% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,145,374
among all websites
- Category rank#4,142
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.6
- Average visit19 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Prothena. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bioworld.com | bioworld.com | 100% | – | #311,180 | – |
| blueprintmedicines.com | 85% | 17.2K | #1,495,010 | View details | |
ir.macrogenics.com | ir.macrogenics.com | 84% | – | – | – |
| neuroderm.com | 84% | 2.8K | #5,643,423 | View details |
Latest news on Prothena
Complete news archive for Prothena
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Prothena
10 companies that operate in the same segment as Prothena (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Prothena
Prothena was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Prothena is headquartered in Dublin, Ireland.
Prothena has 163 employees.
Annual revenue of Prothena is $9.68M as on Dec 31, 2025.
Prothena was founded in 2012 and is headquartered in Dublin, Ireland. Antibody-based therapies are developed by the company for conditions including AL amyloidosis, Parkinsons disease, and psoriasis. Operations are conducted within the biotechnology sector, where research and clinical development focus on protein misfolding disorders and autoimmune diseases. Services encompass drug discovery and therapeutic advancement, with activities spanning preclinical to clinical stages across international collaborations.
Prothena's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Prothena offers Birtamimab, Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), and PRX012.
Yes, Prothena is publicly traded on NASDAQ under the ticker symbol PRTA.
Prothena operates through Prothena Corporation Plc.